Pharmaceutical oligopoly triples the price of insulin taking advantage of diabetes hatching

A pharmaceutical oligopoly triggers the price of insulin taking advantage of the hatching of diabetes
The price of insulin has tripled 10 years in a market dominated by multinationals Novo Nordisk, Sanofi and Elly Lilly

The World Health Organization published on April 7, on the occasion of World Diabetes Day, its first world report on this disease in which it estimated at 422 million people those affected by excess blood glucose, having almostmultiplied by four the number, since in 1980 it was 108 million, having doubled the world prevalence (normalized by age) of the disease, which has gone from 4.7% to 8.5% of the adult population, being the SpanishSuperior, of the order of 9.4% and 10.6% in men.

The seriousness of these figures has stimulated the appetite of the pharmaceutical companies that face a fabulous business in the battle against this epidemic.Recent data published by the American Medical Association (JAMA) show that the price of insulin, injection necessary to treat patients who no longer respond to pills, has tripled, having gone from $ 4.34 per milliliter in 2002 to12.92 dollars in 2013, which means that the annual treatment of a patient with the need for insulin is approaching the 800 dollars (700 euros).

The International Diabetes Federation, which groups the national associations of 170 countries, including Spain, estimates that in 2030 the number of diabetics will exceed 550 million people, which fortunately will have cheap medications due to the expiration of patents, but whose access toThe most modern, especially to the most effective insulin, will be prohibitive.The insulin -producing pharmaceutical industry is an oligopoly in which the Danish Novo Nordisk send, which attributes 47% of the market, the French Sanofi Aventisy the American Elly Lilly.

The business is fable.Nordisk obtained a record benefit of 4,670 million euros last year, with a 32% increase over the previous year, and a huge margin since its turnover was 14,500 million euros (at the change of crowns).The company itself estimates that its insulin is supplied to 24 million people and in a few years it will reach 40 million.85% of the Danish multinational business comes from diabetes, and the extension of this disease and the price of its insulin has made its actions revalue 800% in ten years despite the deep economic recession lived ...

Source: Link